HIV 1/2 Human Immunodeficiency Test

Call For Pricing.

Model Number: NH-70302

Brand: Niche Healthcare

The HIV 1/2 Rapid Test Device (Whole blood/Serum/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of antibodies to HIV 1 and/or HIV 2 in whole blood, serum or plasma specimens.

 

Description

Catalog No. HIV-4012a Format Device
Specimen Whole blood/Serum/Plasma Certificate None CE
Reading Time 10 minutes Test/Kit 40
Storage Temperature 4-30°C Shelf Life 2 Years
Sensitivity >99.9% Specificity >99.9%
Accuracy >99.9% Composition Individually packed test device, Package insert, Dropper, Buffer

 

The HIV 1/2 Human Immunodeficiency Virus Rapid Test Device (Whole blood/Serum/Plasma) can offer several healthcare benefits in the National Health Service (NHS) or any healthcare system. Here are potential benefits:

  1. Early Detection of HIV Infection: The rapid test allows for the early detection of antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma, enabling timely diagnosis of HIV infection.

  2. Prompt Initiation of Treatment: Early detection facilitates the prompt initiation of antiretroviral therapy (ART), which is crucial for managing HIV infection and preventing the progression to AIDS. Early treatment improves long-term outcomes and reduces the risk of transmitting the virus to others.

  3. Prevention of Mother-to-Child Transmission: Identifying pregnant women with HIV infection through screening allows for interventions to prevent mother-to-child transmission, such as administering antiretroviral medications during pregnancy and delivery and avoiding breastfeeding in some cases.

  4. Prevention of Transmission: Identifying individuals with HIV allows for the implementation of prevention strategies, such as counseling on safer sex practices and the use of pre-exposure prophylaxis (PrEP) for individuals at high risk.

  5. Care and Support Planning: Early diagnosis enables healthcare providers to initiate appropriate care and support services for individuals living with HIV, addressing physical, mental, and social aspects of health.

  6. Resource Optimization: Rapid tests contribute to efficient resource utilization by providing quick and cost-effective diagnostic information, allowing healthcare providers to prioritize and manage HIV cases more effectively.

  7. Prevention Education: Screening for HIV provides an opportunity for education on risk reduction, safe sex practices, and harm reduction strategies, contributing to public health efforts to reduce new HIV infections.

  8. Point-of-Care Testing: Rapid tests can be performed at the point of care, providing quick results without the need for sending samples to a laboratory. This expedites decision-making, allowing for immediate counseling, treatment initiation, and linkage to care.

  9. Public Health Surveillance: Monitoring the prevalence of HIV infections in the population through rapid testing contributes to public health surveillance efforts. This information helps in planning and implementing preventive measures, targeting resources, and evaluating the impact of public health programs.

  10. Reduction of Stigma: Early diagnosis through rapid testing may contribute to reducing the stigma associated with HIV, as individuals can be informed and supported promptly, and stigma reduction efforts can be initiated.

 

Infectious Disease Trials

Infectious disease trials are conducted to address various aspects related to the prevention, treatment, and understanding of diseases caused by infectious agents, such as bacteria, viruses, parasites, or fungi. Here are some reasons for conducting infectious disease trials:

  1. Vaccine Development: Trials are crucial for testing the safety and efficacy of new vaccines aimed at preventing infectious diseases. This includes vaccines for viruses like influenza, human papillomavirus (HPV), and emerging threats like COVID-19.
  2. Antiviral and Antibiotic Testing: Clinical trials assess the effectiveness of new antiviral medications or antibiotics in treating infections. This is particularly important in addressing antibiotic resistance and finding alternative treatments.
  3. Understanding Disease Mechanisms: Trials help researchers understand the mechanisms of infectious diseases, including how pathogens spread, evade the immune system, and cause illness.
  4. Global Health Concerns: Trials play a vital role in addressing global health concerns, such as emerging infectious diseases (e.g., Ebola, Zika, COVID-19) and ongoing challenges like malaria, tuberculosis, and HIV.
  5. Public Health Interventions: Trials evaluate the effectiveness of public health interventions, such as strategies for disease prevention, control, and containment.
  6. Drug and Treatment Development: Researchers conduct trials to develop and test new drugs or treatment regimens for infectious diseases, aiming to improve outcomes for affected individuals.
  7. Surveillance and Epidemiology: Clinical trials contribute to surveillance efforts by providing data on disease prevalence, transmission patterns, and the effectiveness of control measures.

Infectious disease trials are essential for advancing our understanding of these diseases, developing effective interventions, and ultimately improving global public health. They contribute significantly to the development of evidence-based strategies for preventing, treating, and managing infectious diseases.

 

Types of Infections

Types of Infections

 

For more information, contact us 01274 965089 or check out our website at www.nicheofficesolutions.co.uk www.nicheofficesolutions.co.uk/niche-nhs

Further clinical information can be found on our blog page: www.nicheofficesolutions.co.uk/category/niche-healthcare-news

For products not found on our online website, please view our Healthcare catalogues: www.nicheofficesolutions.co.uk/healthcare-catalogues

View our Healthcare YouTube videos Playlist

If you have any additional questions, drop us an email at info@nicheofficesolutions.co.uk 

Reviews

There are no reviews yet.

Be the first to review “HIV 1/2 Human Immunodeficiency Test”